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AbstrAct:
More effective anticancer agents are essential, as has too often been 
demonstrated by the paucity of therapeutics which preserve life. Their discovery 
is very difficult. Many approaches are being applied, from testing folk medicines 
to automated high throughput screening of large chemical libraries. Mutations 
in cancer cells create dysfunctional regulatory systems. This Perspective 
summarizes an approach to applying defective  molecular control mechanisms 
as oncotargets on which drug discoveries against cancer can be based.
INtrODUctION 
The molecular basis of cancer is becoming 
understood, and is thoroughly reviewed [1]. But the 
promise  of  cancer  drug  therapy  is  unfulfilled.  ‘Magic 
bullets’ against the disease have not been discovered. 
Chemotherapy  often  only  briefly  extends  life  and  has 
severe  side  effects.  As  examples,  the  combination  of 
paclitaxel and anthracycline is often used against breast 
cancer, although it benefits only 30% of patients. Drugs 
are not effective against stage IV melanoma; about half 
the patients develop metastases [2]. 
Improvements of cancer treatment are sorely needed. 
A major problem is selective lethality against cancer cells. 
Many drugs kill cancer cells in culture and in mice, but 
also kill normal cells and have severe side effects. This 
limits drug dosage. Another problem is that cancers 
respond differently to chemotherapy, as do five principal 
subtypes  of  breast  cancer  [3].  Discovery  and  clinical 
testing of an effective anticancer drug is enormously 
difficult and expensive; developing a potential drug can 
cost over 800 millions of dollars. Millions of chemicals, 
randomly synthesized even without a lead compound, 
are being screened and tested with rapid endpoints such 
as their lethality to cultured cancer cells. It is timely to 
summarize attempts to develop cancer therapies from 
the abnormal molecular regulatory mechanisms that are 
necessary for progression of cancer.
I. NOrmAl cell regUlAtOry 
bIOlOgy AND ONcOtArgets
Approaches to discovering oncotargets can be based 
upon biochemical pathways of small molecule, protein 
and nucleic acids synthesis and degradation. These are 
qualitatively similar between normal and cancer cells, but 
their regulatory processes, either lost or constitutive in 
cancers [4] are more likely to provide oncotargets.
Major molecular biological regulatory mechanisms 
were  discovered  fifty-plus  years  ago.  These  include 
covalent  enzyme  modifications  catalyzed  by  kinases, 
non-covalent  binding  by  small  molecules  that  rapidly 
feedback  inhibit  their  own  synthesis,  e.g.,  metabolic 
feedback  inhibition,  protein-protein  interactions  alone 
or in multiprotein complexes, control of gene activation 
by repression, and functional activities of membranes. 
Another level of regulation is transport of small molecules 
including metabolites, drugs and regulators through 
the lipid bilayer cell membrane. Lipophilic molecules 
diffuse into the cytoplasm, but charged metabolites such 
as amino acids and nucleotides can require specific and Oncotarget 2010; 1:  544 - 551 545 www.impactjournals.com/oncotarget
energy-requiring enzyme-like permease channels. As an 
example, a ring of core proteins with attached regulatory 
calcium ion binding proteins is a ‘gate’ for potassium ions 
[5]. These changed regulatory mechanisms can provide 
targets for discovery of new treatments. 
II. mOlecUles esseNtIAl fOr 
cANcer cell grOwth AND/Or 
sUrvIvAl. 
mutations
Cancer cells deviate from normal cells due to 
mutations. An advanced tumor is composed of cells that 
have undergone diverse and numerous mutations, creating 
cells with many different properties. Thousands of 
changed gene expression have been found, but most do not 
appear in most cancers and are not essential. They might 
be caused by secondary mutations. Mutations increase as 
cancer develops, at least in part because the DNA repair 
mechanisms are defective, creating genetic instability 
[6]. Telomere loss is also a mechanism for chromosome 
instability  [7].  DNA  structure  is  thereby  changed  and 
alters amounts and characteristics of enzymes and other 
proteins. These mutations can stimulate oncogenes or 
inactivate  tumor  suppressor  genes.  In  extreme  cases 
mutation completely eliminates production of a protein. 
Therapies are being designed that target repair mechanisms 
[8]). Targeting a cancer driven by an activating mutation 
of B-raf is showing promise. A highly potent and specific 
B-raf inhibitor induced regression of melanoma in 80% of 
patients bearing activating B-raf mutations [9]. 
Epigenetics, heritable changes other than of the 
genomic sequence, have recently become of major 
interest.    Gene  expressions  can  be  modified  by  post-
synthetic  methylations  of  DNA  or  of  methylation  and 
acetylation of associated histones in chromatin of 
eukaryotes [10]. They are heterogeneous in patients [11]. 
Epigenetic  modifications  are  involved  in  plasticity,  the 
capacity of alteration of a cell’s phenotype in response 
to changes in environment [12]. They can modify gene 
expressions for many cycles, as during differentiation of 
stem cells [13], and could become permanent, and thereby 
involved during cancer progression, in loss of cells ability 
to differentiate and become quiescent [14].
Epigenetic oncotargets are abundant [15] and are 
being applied for drug development [16]. Advancements 
that include targeting histone methylation [17], and 
mitochondria inner membrane transporters [18] may 
provide novel therapeutic strategies that compliment/
synergize with the current available modalities.
Furthermore, cancer stem cells, a very small 
subpopulation of cells with different properties from the 
majority, appear to be fundamental to tumor progression. 
Cancers become resistant to treatment; the tumor can 
shrink but the patient will die because lethal stem cells 
survive. These are proposed to be crucial targets for 
therapy [19]. A strategy that includes finding oncotargets 
present in cancer stem cells may help alleviate this 
resistance to therapy. BB1608, a first-in-class cancer stem 
cell stemness inhibitor is in clinical trials with promising 
phase I data (Langebland, AACR, 2010). Development of 
methods for producing immortalized mammary stem cells 
that can self replicate and differentiate should greatly help 
discovery of stem cell oncotargets [20]. 
metastasis and oncotargets 
Processes that can provide oncotargets are 
molecular changes that cause defective proliferation, 
block  programmed  cell  death  (apoptosis)  under  stress, 
production of new blood vessels (angiogenesis), and drug 
resistance, and escape of cells to initiate secondary tumors 
(metastasis). 
Metastasis  appears  in  cancer  progression,  and  is 
a  key  step  leading  to  malignancy  and  cancer  lethality 
[21.  Epithelial  cells  undergo  transition  (EMT)  to  a 
mesenchymal phenotype with loss of cell-cell adhesion, 
more  motility  and  greater  invasiveness.  EMT  involves 
several molecules that could provide oncotargets, such 
as the metalloproteases that decrease cell adhesion. As an 
example, kinase Akt1 was found to be hyperphosphorylated 
when breast cancer cells became metastatic [22].  This 
study illustrates the increased difficulty of treatment as a 
cancer develops: Akt is also a key regulator of cell growth, 
apoptosis and migration. It has roles in neurological and 
other diseases. There are three isoforms of Akt with some 
overlapping functions, although each isoform of Akt has 
unique downstream targets. Growth factors binding to 
receptor tyrosine kinases (e.g., IGFR, erbB2) recruit Akt 
to translocate to the cytoplasmic membrane where Thr308 
on its activation loop and Ser473 on the hydrophobic motif 
are phosphorylated by PDK1 and mTORC2, respectively, 
leading to Akt activation. 
Activation is reversed by phosphatases. PP2A 
dephosphorylates  Thr308  of  Akt.  In  a  search  for  a 
phosphatase  containing  a  PH  domain  that  could  co-
localize with Akt near plasma membrane, PHLPP (PH 
domain leucine rich repeat protein phosphatase) was 
discovered to be the long sought after phosphatase for 
Ser473 of Akt [23]. PHLPP containing a PP2C domain 
is a member of the serine/threonine phosphatase family 
Expression  of  PHLPP  protein  and  mRNA  are  much 
decreased in the metastatic cell line of the breast cancer 
progression series 21T [22]. There are two isoforms; 
PHLPP1b (SCOP) with an N-terminus extension is 1.5kb 
longer than PHLPP1a. Another PHLPP family member, 
PHLPPL  that  dephosphorylates  Ser473  Akt  was  later 
identified [24]. 
The requirement of domains for PHLPP functioning Oncotarget 2010; 1:  544 - 551 546 www.impactjournals.com/oncotarget
is substrate dependent, as PH domain is essential for PKC 
and PDZ domain is required for Akt dephosphorylation. 
There are several highly conserved domains in PHLPP 
and PHLPPL, including PH domain, leucine rich 
repeat,  PP2C  domain  and  PDZ  binding  motif.  PHLPP 
and  PHLPPL  specifically  dephosphorylate  distinct Akt 
isoforms.  PHLPP  exhibits  high  preference  for  Akt  2, 
3, while PHLPPL has Akt 1, 3 as substrates. FKBP51 
(FK506-binding protein 51) acts as a scaffolding protein 
for Akt and PHLPP and promotes dephosphorylation of 
Akt by PHLPP [25]. Besides Akt, PKC family members 
(PKCa,  PKCbII)  were  also  identified  as  substrates  for 
PHLPPs [26]. 
PHLPP is a proteolytic target of b-TrCP (the substrate 
recognition  subunit  of  SCF-Ub  E3  ligase  complex). 
Phosphorylation of four sites on the PP2C domain of 
PHLPP  by  casein  kinase  I  and  GSK3b will promote 
binding of PHLPP to b-TrCP that leads to ubiquitination 
and degradation of PHLPP [27]. 
There are over 400 known Ser/Thr kinases and far 
fewer (~30) Ser/Thr phosphatases. PHLPPs are predicted 
to have more substrates other than Akt and PKCa. Mst1 
(Mammalian sterile 20-like kinase 1) was identified as 
a  substrate  for  PHLPPs  [28].  Mst1  participates  in  the 
regulation of mammalian cell morphology, motility and 
apoptosis  by  activation  of  mitogen-activated  protein 
kinase  (MAPK).  Mst1  exists  in  auto-inhibitory  dimers 
maintained  by  phosphorylation  at  Thr387.  The  PP2C 
domain of PHLPP interacts with Mst1 to dephosphorylate 
Thr387 in the inhibitory domain of Mst1 that leads to 
auto-phosphorylation on Thr183. FOXO, JNK and p38 
pathways then become activated to promote apoptosis. 
Interestingly, Akt  and  Mst1  are  reciprocally  inhibitory. 
The Thr387 site of Mst1 can be phosphorylated by Akt 
and become inactivated. Mst1 could inhibit Ser473 Akt 
phosphorylation. Therefore, PHLPP, Akt and Mst1 form 
an intricate triangle to orchestrate the fine balance of cell 
survival and apoptosis in normal cells. 
PHLPP, a tumor suppressor, is present in the majority 
of  human  tissues.  Its  expression  is  much  decreased 
in human colon, pancreatic and gastric cancer patient 
specimens [28][29]. Over-expression of PHLPP reduces 
the tumorigenesis of glioblastoma and colon cancer cells 
in a xenograft nude mice model. In PHLPP1-null mice 
impaired capacity to stabilize circadian periodicity after 
light-induced resetting is observed [30]. 
In  another  PHLPP  knockout  mouse  model  Akt 
phosphorylation elicited by ischemia/ reperfusion injury 
is  enhanced;  thereby  Akt  exerts  its  cardio-protective 
effect to reduce infarct size [31]. PHLPP (SCOP) was 
originally identified as an oscillating protein in the SCN 
nucleus that plays important roles in circadian rhythms. 
In addition, it regulates ERK signaling by interacting with 
Ras to modulate long-term memory [32]. How PHLPPs 
become activated is still under intensive investigation. 
As our understanding evolves, more PHLPP oncotargets 
will be identified and more function of PHLPPs will be 
discovered. The PHLPP-Akt-Mst1 pathway, deregulated 
in tumors, may result in more specific cancer therapeutics 
that minimize off target effects.
cell proliferation. 
Analysis of steps in the cell cycle, has been 
extensively  investigated  to  identify  oncotargets  that 
lead to defective proliferation [33]. Extracellular factors 
greatly  modify  initiation  of  proliferation.  Normal  cells 
are  arrested  in  G1  phase,  prior  to  DNA  synthesis,  by 
contacts with adjacent cells and the extracellular protein 
matrix, but tumor cells continue to cycle. Epithelial cell 
adhesion molecule EpCAM is over expressed in cancer 
initiating cells. It is regulated negatively by the tumor 
necrosis factor alpha [34]. Lipophilic hormones (estrogen 
and androgen) permeate through cell membranes, bind 
to nuclear receptors, and activate gene expressions [35]. 
This process provides oncotargets for synthetic analogs 
that are applied against estrogen and androgen -receptor 
over-expressing tumors.
 Extracellular binding of a growth factor protein to 
its trans-membrane receptor initiates cytoplasmic kinase 
cascades, such as MAP kinases that activate transcription 
factors in the nucleus. Epidermal growth factor (EGF) 
binds to the Her2/neu receptor on membrane of quiescent 
cells,  which  leads  to  the  intracellular  protein  kinases 
activation. Her2/neu is in excess in about one third of 
breast cancers, and provides an oncotarget for drugs and 
for antibodies such as herceptin. The anticancer drug 
imatinib  (Gleevec)  that  inhibits  over  active  Bcr-Abl 
kinase in certain cancers provides an example of a widely 
applied therapy. Many kinases, including PI3K/Akt, have 
now become targets for therapy [36]. 
The  by  induction-repression  mechanism  of 
gene expression in the nucleus is vital for normal cell 
proliferation and function. The first step is transcriptional 
production of RNA, which is spliced into messenger RNA. 
Synthesis  is  countered  by  hydrolysis.  mRNA  provides 
information in their nucleotide sequence for translation 
catalyzed by ribosomes into the amino acid sequence of a 
protein, according to the genetic code. 
  siRNAs  and  microRNAs  (miRNA)  also  regulate 
cell proliferation. These short double-stranded RNAs bind 
to mRNAs with complementary base sequence and target 
them  for  destruction  or  inhibit  their  synthesis.  siRNA 
and miRNA have been widely used in cancer research 
to pinpoint the functions of many genes. This new area 
includes  effects  on  epigenetics  [37].  miRNAs  play 
important roles in tumorigenesis and metastasis. siRNA 
based cancer therapeutics are being actively pursued 
[38][39]. A  micro  RNA,  MiR-21  has  been  reported  to 
be essential for proliferation of many cancers. MiR-21 
is ‘addictive’; tumors regress unless it is produced [40]. 
Synthetic asymmetric RNAs show the promise to improve Oncotarget 2010; 1:  544 - 551 547 www.impactjournals.com/oncotarget
the current siRNA approach [41]. A possible complication 
is that Dicer and Drosha, key proteins involved in siRNA 
processing, were found to be down-regulated in cancers 
with poor outcome ([42]. These enzymes might become 
oncotargets of future therapeutics [43].
DNA synthesis and mitosis as oncotargets.
Numerous  drugs  that  block  DNA  replication  or 
cause damage are applied clinically [1]. The frequent 
uncontrolled DNA synthesis in cancer cells presents an 
oncotarget. Cyclin D and E are proteins synthesized in G1 
phase of the cell cycle. They bind to and activate two cyclin 
dependent kinases, which phosphorylate retinoblastoma 
protein [44], thereby releasing DNA polymerase activity 
and entry into S phase. Cleaved low molecular weight 
cyclin E is found in many cancers, and is associated with 
poor prognosis [45]. 
Mitosis  is  a  cycle  related  oncotarget.  An  early 
approach to drug discovery was to give a natural product 
such as one used in herbal medicine to a tumor-bearing 
animal and determine whether it is beneficial. One well-
known example is Taxol (paclitaxel), whose oncotarget 
is microtubules in mitosis. Several chemically modified 
Taxol derivatives were synthesized, tested for effect on 
mitosis, and Taxol and Taxotere are presently applied as 
anticancer drugs.
b-Lapachone , in a folk medicine isolated from a 
tree’s bark, selectively kills cancer cells in culture and 
in animals (46). It kills non-small lung cancer cells with 
elevated mitochondrial enzyme NQO1 by futile cycling 
of electron transport, which decreases production of 
ATP and NAD and produces toxic reactive oxygen [47]. 
b-Lapachone acts by at least two mechanisms because 
a four -fold higher dose also kills NQO1-negative cells 
[46]. Production of cellular energy (ATP) in normal cells 
is mainly by oxidation in mitochondria, versus increased 
glycolysis in cytoplasm of cancer cells. This is a classical 
example of a different biochemical process that provides 
an oncotarget [48]. Several drugs that act on mitochondrial 
functions are being developed [49]. 
Protein synthesis and removal 
Synthesis of enzymes and other proteins are central 
to regulation of biochemical processes. Enzymes that 
degrade proteins are closely regulated in normal cells. 
Excessive  cancer  cell  proliferation  depends  upon  short 
lived proteins. in particular cyclins , whose degradation 
can be defective. Protein synthesis is counterbalanced 
by degradation. Small proteases are not yet successful 
oncotargets; they can degrade both activating and 
inhibiting regulatory proteins, and drugs that inhibit them 
have  complex  effects.  The  proteasome,  a  large  (about 
50  subunit  proteins)  complex,  mediates  degradation  of 
many proteins after they have been specifically tagged 
by attachment of ubiquitin proteins [50]. The proteasome 
inhibitor Velade (bortezomib) is applied clinically 
against multiple myeloma and mantle cell lymphoma; its 
combinations with other drugs are being tested against 
several types of malignancies. A protease blocks activation 
of  NF-kB.  Its  inhibitors  thereby  are  pro-apoptotic  for 
cancer cells, and are being investigated. 
cancer cell removal 
Programmed cell death (apoptosis) counteracts 
uncontrolled proliferation of cancer cells. It can be lost 
in cancers, which provides an oncotarget: transcription 
factor  NF-kB  ,  linked  to  inflammation  through  TNFa, 
suppresses apoptosis of stressed cancer cells. The drug 
Go6976  blocks  NF-kB  activation,  inhibits  growth  and 
causes degeneration of estrogen receptor negative breast 
cancers in vivo without detected damage to vital organs 
[51]. In vivo and in vitro experiments suggest that Go6796 
blocks  activation  and  anti-apoptotic  activity  of  factor 
NF-kB by inhibiting protease caspase-8 [52]. Apoptosis 
of tumor cells was also sensitized by a polypeptide that 
specifically neutralizes anti-apoptotic protein MCL-1, and 
sensitizes cancer cells to drugs [53]. Drugs that promote 
respiration can selectively cause apoptosis of cancer 
cells [54]. Cells under stress release apoptotic protein 
cytochrome C from their mitochondria. siRNAs control 
apoptosis,  among  many  processes  [55].  Natural  [56] 
and modified [57] siRNAs are being tested for specific 
anticancer activities 
Angiogenesis, another source of oncotargets
Blood vessel formation within a large cancer is 
required to provide oxygen and metabolites required to 
permit proliferation of internal cells. These vessels also 
allow released cancer cells to travel to distal sites and seed 
new cancers (metastasis), a process that correlates with 
lethality. Anti-angiogenesis  agents  such  as Avastin  can 
block tumor growth [58]. Pleiotrophin is a cytokine that 
induces tumor angiogenesis by binding to and inhibiting 
its transmembrane receptor tyrosine phosphatase. It 
also induces the association of b-catenin with cadherins 
EMT, and many other properties associated with tumor 
promotion [59].
III. fUtUre ONcOtArget relAteD 
bAsIc reseArch AND therAPeUtIcs.
Cancers progress from bad to worse. Biomarkers for 
early detection thus are highly important [60]. Biomarkers 
are also being sought for improved diagnosis, and for early 
determination of efficacy of therapy. Markers associated 
with melanoma include circulating tumor cells in blood Oncotarget 2010; 1:  544 - 551 548 www.impactjournals.com/oncotarget
[61], and molecular markers for tumor progression [62]. 
Apoptosis of cancer cells releases biomarkers into blood 
including  postranslational  modifications  of  proteins 
[63], which can be detected in very small non-invasive 
samples  [64].  miRNAs  in  cancers  are  changed  [65]. 
Urine  of  prostate  cancer  patients  contains  an  siRNA 
biomarker; pooled samples were analyzed by differential 
display for selection of the most frequently changed 
biomarkers  .  Pooling  should  be  valuable  for  finding 
frequently expressed potential oncotargets and to simplify 
research effort [66]. Biomarkers for colon and pancreatic 
cancers are found in fecal samples. Techniques for 
biomarker discovery include genome sequencing, arrays 
and  differential  display-related  methods,  proteins  and 
phosphoproteins, antibodies, electrophoretic 2D gels, and 
nuclear magnetic resonance spectroscopy [67]. 
systems biology
The quantity and complexity of information about 
cancer presents a problem. Creation of cell phenotypes 
involves activities and regulation of groups of genes. 
More than one mutation is usually needed to make a hit, 
oncotargets are likely to act in sets, multi-drug combinations 
are superior to a single drug [68]. Comprehensive therapy 
based on oncotarget research should be bases on complex 
system models [69]. Systems biology is an approach to 
quantitate and visualize the massive information that links 
molecular biological pathways and their regulations. This 
modeling could provide a basis for studies of defective 
controls in cancers [70]. Negative and positive feedback 
loops [71] and bifan switching mechanism [72] have been 
discovered  in  cell  signaling  networks  [73].  These  can 
identify oncotargets as for metastasis [74] and for drug 
discovery [75].They are incorporated in stem cell systems 
[76]. 
Models of differentiation of normal cells from stem 
cells and regulations of their phenotypic changes [77] 
could be constructed based on systems biology . Pattern 
formation in oogenesis provides a dramatic example [78] 
Systems  biology  could  move  “reductionism”  [79]  into 
general biology [80]: ‘Nature’ is regulated by ‘Nurture’. 
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